The stock is a binary event play on the Fortitude merger closing in Q4 2026. Near-term fundamentals are deteriorating (widening losses, no revenue, negative equity). Traders should monitor shareholder vote timing and any regulatory hurdles for the merger, as the current operating business has no clear path to standalone profitability. The ATM facility and related party stock sales add dilution risk.
Price Chart
Executive Summary
HeartSciences reported FQ1 2027 results with no meaningful revenue and a net loss of $3.2M, wider than the $2.1M loss a year ago. EPS of -$0.87 missed consensus of -$0.72 by 20.8%. The company is pivoting toward a proposed merger with Fortitude Mining (Zcash miner), which is expected to close in Q4 2026, while de-emphasizing its legacy MyoVista wavECG device. The stock is a micro-cap with high uncertainty and a history of volatile moves around filings, but the core operating story remains pre-revenue and loss-making, making this a neutral-to-bearish read on fundamentals alone, offset by the pending transformative deal narrative.
Key Financial Metrics
Key Facts
- No meaningful revenue reported for FQ1 2027; net loss widened to $3.2M from $2.1M a year ago.
- EPS of -$0.87 missed consensus of -$0.72 by 20.8% (surprisePct -20.8%).
- Proposed business combination with Fortitude Mining (Zcash miner) continues to progress, expected to close in Q4 2026.
- Company recorded a $0.3M inventory reserve against the MyoVista wavECG device and does not intend to commit significant resources to its commercialization.
- Since quarter end, raised ~$2.2M in gross proceeds from Fortitude stock sale and ATM facility, plus $200K note exchange.
Financial Impact
Net loss of $3.2M vs $2.1M YoY; EPS miss of -$0.87 vs -$0.72 consensus; no revenue; $2.0M shareholders' deficit as of July 31, 2026.
Risk Factors
- Merger may not close or may be delayed beyond Q4 2026.
- No revenue and widening losses; shareholders' deficit of $2.0M indicates financial distress.
- Dilution from ATM facility and related party stock issuances.
- MyoVista wavECG device commercialization abandoned; FDA 510(k) outcome uncertain and now strategically irrelevant.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3362228 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 26, 2026 today | DEFA14A | $3.18 | awaiting T+1 | — | $3.18 (+0.00%) |
Oct 26, 2026 today | DEFA14A | $3.14 | awaiting T+1 | — | $3.18 (+1.27%) |
Oct 23, 2026 3d ago | SC 13D/A | $3.41 | awaiting T+1 | — | $3.18 (−6.74%) |
Oct 21, 2026 5d ago | DEFA14A | $3.17 $3.14 | ▼ −0.95% | ▼ −0.42% | $3.18 (+0.32%) |
Oct 19, 2026 7d ago | DEFA14A | $3.13 $3.56 | ▲ +13.74% | ▲ +13.21% | $3.18 (+1.60%) |
Oct 19, 2026 7d ago | DEFA14A | $3.07 $3.13 | ▲ +1.95% | ▲ +1.62% | $3.18 (+3.58%) |
Oct 19, 2026 7d ago | DEFM14A | $3.07 $3.13 | ▼ −1.95% | ▼ −1.62% | $3.18 (−3.58%) |
Oct 15, 2026 11d ago | DEFA14A | $3.02 $3.07 | ▲ +1.66% | ▲ +1.23% | $3.18 (+5.30%) |
Oct 9, 2026 17d ago | 424B5 | $3.30 $3.09 | ▲ +6.36% | ▲ +6.35% | $3.18 (+3.64%) |
Oct 6, 2026 20d ago | DEFA14A | $3.49 $3.04 | ▼ −12.89% | ▼ −12.47% | $3.18 (−8.88%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers